StockMacro
Menu

CalciMedica

$1.26 -67% in 6 monthsMarket cap $8.7M

CALC on XNAS, Health Care, CalciMedica, Inc., job postings

Measures activity, not value. Not investment advice.

Shares fell 92% in a year while institutional holders dropped from 31 to 17 last quarter.

  • BadNet loss of $15.1M over 12 months, against $13.8M cash

Written by AI from the data on this page, 22 Nov 2026. Not investment advice.

Profile and fundamentals

From its SEC filings, 12 months to 30 Sep 2026

CalciMedica Inc is a clinical-stage biopharmaceutical company focused on developing therapeutics that treat serious illnesses driven by inflammatory and immunologic processes and direct cellular damage. Its product candidates act upon calcium release-activated calcium (CRAC) channels and would constitute a new class of drugs. Its product candidate is Auxora, a potent and selective intravenous formulated small molecule CRAC channel inhibitor containing the active compound zegocractin (formerly referred to as CM4620) that, in animal models, reduced acute epithelial and/or endothelial cell injury and inflammation in organs, such as the pancreas, lungs and kidneys. The company operates as one operating segment focused on developing and commercializing therapeutics in the U.S.

Industry
Pharmaceutical preparations (Health Care)
Employees
12
Website
calcimedica.com
Listed
Nasdaq, US
Last results
10 Nov 2026
Next results
expected around 2 Mar 2027 (an estimate: a year ago it reported on 3 Mar 2026)
Revenue and net income per quarter. Quarter to 30 Sep 2026: net loss $1.7M.
Quarter to 31 Dec 2021: revenue –, net income -$8.7MQuarter to 31 Mar 2022: revenue –, net income -$10.1MQuarter to 30 Jun 2022: revenue –, net income -$8.2MQuarter to 30 Sep 2022: revenue –, net income -$9.8MQuarter to 31 Dec 2022: revenue –, net income -$7.4MQuarter to 31 Mar 2023: revenue –, net income -$19.3MQuarter to 30 Jun 2023: revenue –, net income -$6.3MQuarter to 30 Sep 2023: revenue –, net income -$4.6MQuarter to 31 Mar 2024: revenue –, net income $130KQuarter to 30 Jun 2024: revenue –, net income -$4.0MQuarter to 30 Sep 2024: revenue –, net income -$5.6MQuarter to 31 Dec 2024: revenue –, net income -$4.3MQuarter to 31 Mar 2025: revenue –, net income -$5.0MQuarter to 30 Jun 2025: revenue –, net income -$6.0MQuarter to 30 Sep 2025: revenue –, net income -$7.8MQuarter to 31 Dec 2025: revenue –, net income -$10.8MQuarter to 31 Mar 2026: revenue –, net income $5.0MQuarter to 30 Jun 2026: revenue –, net income -$7.7MQuarter to 30 Sep 2026: revenue –, net income -$1.7M
31 Dec 2021RevenueNet incomeNet losstallest bar $19.3M30 Sep 2026
See the numbers
Quarter toRevenueNet income
30 Sep 2026–-$1.7M
30 Jun 2026–-$7.7M
31 Mar 2026–$5.0M
31 Dec 2025–-$10.8M
30 Sep 2025–-$7.8M
30 Jun 2025–-$6.0M
31 Mar 2025–-$5.0M
31 Dec 2024–-$4.3M
30 Sep 2024–-$5.6M
30 Jun 2024–-$4.0M
31 Mar 2024–$130K
30 Sep 2023–-$4.6M
30 Jun 2023–-$6.3M
31 Mar 2023–-$19.3M
31 Dec 2022–-$7.4M
30 Sep 2022–-$9.8M
30 Jun 2022–-$8.2M
31 Mar 2022–-$10.1M
31 Dec 2021–-$8.7M
Fundamentals, 12 months to 30 Sep 2026
MeasureLatestYear beforePeer median
RevenueSales over the last 12 months reported. – –
Revenue growthRevenue of the last 12 months compared with the 12 months before. – +11%
Net incomeProfit after all costs and taxes over the last 12 months reported. Negative is a loss. -$15.1M -$23.1M
EPS (diluted)Earnings per share: net income divided by the shares, counting options and convertibles. Left blank when the figures as filed do not fit today's share count (after a split). – –
Gross marginWhat is left of each dollar of sales after the direct cost of making the product or service. – – 73.2%
Operating marginOperating income as a share of sales: profit from the business before interest and taxes. – – -25.0%
Net marginNet income as a share of sales: what the owners keep of each dollar sold. – – -18.2%
Return on equityNet income of the last 12 months divided by shareholders' equity (the average of the latest balance sheet and the one a year earlier): the profit made on the owners' money. – -58.8%
Free cash flowCash from operations minus capital spending over the last 12 months: cash the business produced. – -$21.3M
CashCash, cash equivalents and short-term investments on the latest balance sheet. $13.8M $14.1M
DebtShort- and long-term borrowings on the latest balance sheet. Operating leases are not counted. – –
Net debtDebt minus cash. Negative means the company holds more cash than it owes (net cash). – –
Debt to equityDebt divided by shareholders' equity on the latest balance sheet: how much is borrowed for each dollar the owners have in the company. Blank when equity is negative. – 0.0
Book value per shareShareholders' equity (assets minus liabilities) on the latest balance sheet divided by the shares outstanding. $0.61
P/EPrice to earnings: market cap divided by net income of the last 12 months. What investors pay for one dollar of yearly profit. Blank when the company made a loss. loss 19.3
P/SPrice to sales: market cap divided by revenue of the last 12 months. – 5.0
EV/SalesEnterprise value (market cap plus debt minus cash) divided by revenue of the last 12 months. – 5.0
P/BPrice to book: market cap divided by shareholders' equity on the latest balance sheet. Blank when equity is negative. 2.1 2.0

Latest = 12 months to 30 Sep 2026; balance-sheet lines at its end. Peer median: companies in the same industry (SIC code), or the sector when the industry is small.

Peers nearest by market cap, its own industry first

CompanyMarket capP/EP/SRevenue growthNet margin
CalciMedicaCALC (this company) $8.7Mloss–––
Aethlon MedicalAEMD $8.8Mloss–––
BioVieBIVI $8.6Mloss–––
Lexaria BioscienceLEXX $8.5Mloss–-69%–
VyomeHIND $8.4Mloss–––
Moleculin BiotechMBRX $8.2Mloss–––

Insider Buy/Sell Shares the company's insiders (directors, officers and owners of 10% or more) bought minus what they sold on the open market in the last 90 days, from their Form 4 filings.

–

No data for this company

Institutional holders The number of institutional investment managers (13F filers: funds, pensions, asset managers) reporting the stock, compared with the quarter before. 13F reports are public 45 days after quarter end and show long positions only.

-45%

17 13F filers vs 31

Institutional ownership Shares held by 13F filers at the latest quarter end, divided by the shares outstanding in the company's latest filing. Above 100% usually means a stale share count or double counting, and is marked.

25%

1.7M shares held by 13F filers (30 Sep 2026) of 6.9M outstanding (5 Nov 2026)

Short interest Shares sold short and not yet bought back, divided by the shares outstanding in the company's latest filing. From FINRA's latest short interest report: FINRA reports twice a month and publishes 7 business days after the settlement date. Above 100% means a stale share count, and is marked.

2.5%

171K shares sold short (30 Oct 2026) of 6.9M outstanding (5 Nov 2026)

Days to cover Short interest divided by the stock's average daily trading volume, as FINRA publishes it: how many days of normal trading it would take short sellers to buy back every share. Latest report.

1.8

171K shares sold short (30 Oct 2026) divided by the stock's average daily volume, as FINRA publishes it

Short interest change How the number of shares sold short changed between FINRA's two latest reports, about two weeks apart.

+178%

62K shares sold short in the report before, 171K on 30 Oct 2026

Short sale volume Share of the stock's latest daily volume on FINRA-reported off-exchange venues that was sold short. Market makers sell short routinely, so 40% to 50% is normal; compare it with the company's own 1-year average in the cell's details. A daily flow, not short interest.

48%

48% of off-exchange volume on 20 Nov 2026 was short sales; 1-year average 42%

Open jobs Job postings open on the company's own careers site today, where we track it. Blank when we do not track this company's careers site yet.

–

We do not track this company's careers site yet.

Open jobs change How the number of open job postings changed over the last 30 days: total hiring demand, any job, any country. Shown only once we have tracked the company for 30 days.

–

We do not track this company's careers site yet.

Employees Total staff the company reported in its latest annual report (10-K), with the change from the year before when both years are reported.

–

No headcount in its annual reports in our data.

Visa hiring (foreign workers) Applications to hire foreign specialists on H-1B and E-3 visas certified by the Labor Department in the last 12 months, compared with the 12 months before. This is NOT total hiring: most hires need no visa. Open jobs shows total hiring where we track it.

–

No data for this company

Revenue growth Sales in the latest reported quarter compared with the same quarter a year earlier.

–

No data for this company

Capital spending Money spent on buildings, machines and equipment in the latest quarter, compared with the same quarter a year earlier.

–

No data for this company

Federal contracts Money the US government committed to the company in contracts and grants over the last 12 months.

–

No data for this company

Lobbying What the company reported spending on federal lobbying over the last four quarters.

–

No data for this company

Layoff notices Workers named in state WARN layoff notices over the last 12 months (employers must file them 60 days before a large layoff).

–

No data for this company

News (7d) Articles about the company published in the last 7 days, from our Google News collection (one search per company, every half hour). Blank when we do not collect news for this company.

3

3 articles in the last 7 days; its usual week has 1 (the median of the 26 weeks before).

News vs usual Articles in the last 7 days divided by the company's usual week: the median week of the 26 weeks before. Blank when the usual week has fewer than one article.

3.0×

3 articles in the last 7 days; its usual week has 1.

Price $1.26 on 20 Nov 2026, -92% over 12 months (12-month range $1.02 to $33.70)

  • Sharp change
  • 8-K and other filings
Insider net buying (open market). Insiders bought a net $199K in the last 12 months (the 12 months before: $260K).
Capital spending per quarter. Capital spending $0 in the latest quarter, -100% on a year earlier.
Institutional holders (13F filers). 17 13F filers reported holding it in the latest 13F quarter, -45% on a year earlier.

Every point sits on the day the fact became public (filing acceptance or publication), not the day it happened; prices through 20 Nov 2026. Hover or tap a marker for the fact; click it for the evidence or the source. No data here for: h-1b/e-3 applications certified, revenue per quarter, federal obligations, lobbying spend, workers in warn layoff notices.

See the numbers
Dated facts on the price chart (newest 100)
Became publicKindFact
16 Oct 20268-K and other filingsDirector or officer change
19 Aug 20268-K and other filingsDirector or officer change
18 Aug 2026Sharp changeShort interest spike: short interest spike, 503K vs usual 108K (2026-07-31); 10.6x the same period a year earlier
7 Jul 20268-K and other filingsDirector or officer change
7 Jul 2026Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
18 Mar 20268-K and other filingsDelisting notice or listing transfer
17 Feb 2026Sharp changeShort interest spike: short interest spike, 700K vs usual 76K (2026-01-30); 10.1x the same period a year earlier
27 Jun 20258-K and other filingsDirector or officer change
27 Jun 2025Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
6 Jun 20258-K and other filingsChanged its auditor
14 Jan 20258-K and other filingsDirector or officer change
8 Nov 20248-K and other filingsDirector or officer change
28 Aug 2024Sharp changeClustered insider buying: clustered insider buying (3 independent filers, 4 filing(s) in 30 days, value_usd total 243K)
27 Aug 20248-K and other filingsDirector or officer change
27 Aug 2024Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
10 Apr 20248-K and other filingsChanged its auditor
8 Nov 2023Sharp changeClustered insider buying: clustered insider buying (3 independent filers, 5 filing(s) in 30 days, value_usd total 187K)
25 May 2023Sharp changeClustered insider buying: clustered insider buying (5 independent filers, 9 filing(s) in 30 days, value_usd total 121K)
12 May 20238-K and other filingsEarlier financial statements can no longer be relied on
5 May 20238-K and other filingsDelisting notice or listing transfer
4 Apr 20238-K and other filingsPrivate placement of securities (Form D)
22 Mar 20238-K and other filingsDirector or officer change
22 Mar 20238-K and other filingsDelisting notice or listing transfer
22 Mar 20238-K and other filingsCompleted an acquisition or asset sale
3 Mar 20238-K and other filingsDirector or officer change
9 Feb 20238-K and other filingsDirector or officer change
9 Feb 2023Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
28 Dec 20228-K and other filingsDelisting notice or listing transfer
23 Aug 20228-K and other filingsAsset write-down (impairment)
23 Aug 20228-K and other filingsRestructuring costs announced
21 Jun 20228-K and other filingsDelisting notice or listing transfer
18 Apr 20228-K and other filingsDirector or officer change
18 Apr 2022Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
Insider net buying (open market)
Month from 1 Apr 2022: -$3K published
Month from 1 May 2023: $121K published
Month from 1 Jun 2023: $105K published
Month from 1 Aug 2023: $10K published
Month from 1 Nov 2023: $202K published
Month from 1 Dec 2023: $2K published
Month from 1 Jan 2024: $3.4M published
Month from 1 Apr 2024: $16K published
Month from 1 Jun 2024: $16K published
Month from 1 Jul 2024: $208K published
Month from 1 Aug 2024: $243K published
Month from 1 Nov 2024: $1.2M published
Month from 1 Dec 2024: $13K published
Month from 1 Jun 2025: $38K published
Month from 1 Jul 2025: $65K published
Month from 1 Aug 2025: $76K published
Month from 1 Sep 2025: $68K published
Month from 1 Jun 2026: $199K published
Capital spending per quarter
Quarter ended 31 Mar 2022: $4K, -97% on a year earlier; public on 13 May 2023
Quarter ended 30 Jun 2022: $169K, +0.6% on a year earlier; public on 13 Aug 2022
Quarter ended 30 Sep 2022: $135K, -25% on a year earlier; public on 11 Nov 2022
Quarter ended 31 Mar 2024: $0; public on 15 May 2025
Quarter ended 30 Sep 2024: $6K; public on 14 Nov 2024
Quarter ended 31 Dec 2024: $2K; public on 28 Mar 2025
Quarter ended 31 Mar 2025: $9K; public on 15 May 2025
Quarter ended 30 Jun 2025: $5K; public on 13 Aug 2025
Quarter ended 30 Sep 2025: $8K, +33% on a year earlier; public on 13 Nov 2025
Quarter ended 31 Dec 2025: $6K, +200% on a year earlier; public on 4 Mar 2026
Quarter ended 31 Mar 2026: $0, -100% on a year earlier; public on 13 May 2026
Quarter ended 30 Sep 2026: $0, -100% on a year earlier; public on 11 Nov 2026
Institutional holders (13F filers)
31 Dec 2021 report: 28; public on 14 Feb 2022
31 Mar 2022 report: 27; public on 16 May 2022
30 Jun 2022 report: 25; public on 15 Aug 2022
30 Sep 2022 report: 22; public on 14 Nov 2022
31 Dec 2022 report: 26; public on 14 Feb 2023
30 Jun 2023 report: 12; public on 14 Aug 2023
30 Sep 2023 report: 12; public on 14 Nov 2023
31 Dec 2023 report: 12; public on 14 Feb 2024
31 Mar 2024 report: 20; public on 15 May 2024
30 Jun 2024 report: 21; public on 14 Aug 2024
30 Sep 2024 report: 23; public on 14 Nov 2024
31 Dec 2024 report: 28; public on 14 Feb 2025
31 Mar 2025 report: 29; public on 15 May 2025
30 Jun 2025 report: 26; public on 14 Aug 2025
30 Sep 2025 report: 31; public on 14 Nov 2025
31 Dec 2025 report: 30; public on 17 Feb 2026
31 Mar 2026 report: 27; public on 15 May 2026
30 Jun 2026 report: 31; public on 14 Aug 2026
30 Sep 2026 report: 17; public on 16 Nov 2026

What is unusual now

  • Nothing unusual in the last 90 days: no change appeared. Its most unusual measure now is insider open-market buying (USD, Form 4) at $199K (29 Jun 2026), 21× its normal reading; higher than 89% of its own history.
  • Short interest spike: had 503K shares sold short in the 31 Jul 2026 report, 11× the same report last year Public on 12 Aug 2026.
  • Insider net buying (open market): Insiders bought a net $199K in the last 12 months (the 12 months before: $260K).
  • Capital spending per quarter: Capital spending $0 in the latest quarter, -100% on a year earlier.

Latest records

The names and amounts behind the totals, newest first

Insider trades

All 85 insider trades

No trades in the last 90 days; the latest was filed 29 Jun 2026. Open-market trades by officers, directors and 10% owners.

FiledInsiderTradeSharesPriceValueSource
29 Jun 2026Fred A MiddletonDirector, 10% ownerBuy248,972$0.80$199KForm 4
22 Sep 2025Eric W RobertsCHIEF BUSINESS OFFICERBuy2,500$3.07$8KForm 4
17 Sep 2025Eric W RobertsCHIEF BUSINESS OFFICERBuy3,400$2.68$9KForm 4
15 Sep 2025Eric W RobertsCHIEF BUSINESS OFFICERBuy5,000$3.12$16KForm 4
11 Sep 2025Eric W RobertsCHIEF BUSINESS OFFICERBuy2,343$3.15$7KForm 4
2 Sep 2025Eric W RobertsCHIEF BUSINESS OFFICERBuy10,000$2.85$29KForm 4
25 Aug 2025Eric W RobertsCHIEF BUSINESS OFFICERBuy3,508$2.79$10KForm 4
21 Aug 2025Eric W RobertsCHIEF BUSINESS OFFICERBuy3,000$2.74$8KForm 4

17 institutions reported shares at the end of Q3 2026, 25% of the shares outstanding; 3 opened a position, 17 sold out. From 13F reports.

InstitutionShares% of companyValueChange vs Q2 2026
Woodline Partners LP498K7.22%$807K-2.0M-80%
Armistice Capital, LLC389K5.64%$630KNew+389K
Stonepine Capital Management, LLC279K4.04%$451K-344K-55%
Stempoint Capital LP249K3.61%$403K-996K-80%
Heights Capital Management, Inc164K2.37%$265K-1.4M-89%
Renaissance Technologies LLC48K0.70%$78K-49K-51%
Geode Capital Management, LLC25K0.37%$41K-85K-77%
Cambridge Investment Research Advisors, Inc.16K0.24%-104K-86%
Jane Street Group, LLC15K0.22%$24KNew+15K
Rockefeller Capital Management L.P.4,0000.06%$6K-16K-80%

Company events

All 34 company events

In 12 months: 3 director or officer changes, 2 major agreements, 1 delisting notice. Results releases and routine reports are left out.

FiledWhat happenedSource
16 Oct 2026Director or officer change8-K
19 Aug 2026Director or officer changeSame filing: shareholder vote results8-K
7 Jul 2026Director or officer change8-K
24 Jun 2026Signed a major agreementSame filing: sold shares privately8-K
24 Jun 2026Signed a major agreementSame filing: sold shares privately8-K
18 Mar 2026Delisting notice or listing transfer8-K
27 Jun 2025Director or officer changeSame filing: shareholder vote results8-K
6 Jun 2025Changed its auditor8-K

The 5 newest of 42 articles that name the company.

Timeline
Kind of data

Timeline

Changes and notable records, by the date each became public

  1. 16 Oct 2026Filings record

    Director or officer change

  2. 19 Aug 2026Filings record

    Director or officer change

  3. 12 Aug 2026Short interest and volume change

    had 503K shares sold short in the 31 Jul 2026 report, 11× the same report last year.

    Same report last year: 47K; its normal report is 108K.

    See the evidence
    This period
    503K (the 31 Jul 2026 report)
    Normal report (median of 24 earlier)
    108K
    Typical spread (median absolute deviation)
    58K
    How far from its usual level
    +4.6
    Same report last year
    47K
    History used
    1,218 days
    2025-07-31: 47K2025-08-15: 36K2025-08-29: 63K2025-09-15: 72K2025-09-30: 65K2025-10-15: 55K2025-10-31: 56K2025-11-14: 53K2025-11-28: 64K2025-12-15: 71K2025-12-31: 79K2026-01-15: 80K2026-01-30: 700K2026-02-13: 428K2026-02-27: 392K2026-03-13: 459K2026-03-31: 338K2026-04-15: 372K2026-04-30: 168K2026-05-15: 136K2026-05-29: 144K2026-06-15: 276K2026-06-30: 1.7M2026-07-15: 961K2026-07-31: 503K
    the 31 Jul 2026 report24 earlier reportsnormal: 108K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  4. 7 Jul 2026Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  5. 7 Jul 2026Filings record

    Director or officer change

  6. 30 Jun 2026Insiders record

    Middleton Fred A (director) bought 248,972 shares of CALC ($199,178) (dated 29 Jun 2026)

  7. 18 Mar 2026Filings record

    Delisting notice or listing transfer

  8. 11 Feb 2026Short interest and volume change

    had 700K shares sold short in the 30 Jan 2026 report, 10× the same report last year.

    Same report last year: 69K; its normal report is 76K.

    See the evidence
    This period
    700K (the 30 Jan 2026 report)
    Normal report (median of 24 earlier)
    76K
    Typical spread (median absolute deviation)
    20K
    How far from its usual level
    +12.5
    Same report last year
    69K
    History used
    1,036 days
    2025-01-31: 69K2025-02-14: 93K2025-02-28: 97K2025-03-14: 104K2025-03-31: 110K2025-04-15: 108K2025-04-30: 70K2025-05-15: 131K2025-05-30: 113K2025-06-13: 110K2025-06-30: 107K2025-07-15: 91K2025-07-31: 47K2025-08-15: 36K2025-08-29: 63K2025-09-15: 72K2025-09-30: 65K2025-10-15: 55K2025-10-31: 56K2025-11-14: 53K2025-11-28: 64K2025-12-15: 71K2025-12-31: 79K2026-01-15: 80K2026-01-30: 700K
    the 30 Jan 2026 report24 earlier reportsnormal: 76K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  9. 23 Sep 2025Insiders record

    Roberts Eric W (CHIEF BUSINESS OFFICER) bought 2,500 shares of CALC ($7,675) (dated 22 Sep 2025)

  10. 18 Sep 2025Insiders record

    Roberts Eric W (CHIEF BUSINESS OFFICER) bought 3,400 shares of CALC ($9,112) (dated 17 Sep 2025)

  11. 16 Sep 2025Insiders record

    Roberts Eric W (CHIEF BUSINESS OFFICER) bought 5,000 shares of CALC ($15,600) (dated 15 Sep 2025)

  12. 12 Sep 2025Insiders record

    Roberts Eric W (CHIEF BUSINESS OFFICER) bought 2,343 shares of CALC ($7,380) (dated 11 Sep 2025)

  13. 3 Sep 2025Insiders record

    Roberts Eric W (CHIEF BUSINESS OFFICER) bought 10,000 shares of CALC ($28,504) (dated 2 Sep 2025)

  14. 26 Aug 2025Insiders record

    Roberts Eric W (CHIEF BUSINESS OFFICER) bought 3,508 shares of CALC ($9,787) (dated 25 Aug 2025)

  15. 22 Aug 2025Insiders record

    Roberts Eric W (CHIEF BUSINESS OFFICER) bought 3,000 shares of CALC ($8,230) (dated 21 Aug 2025)

  16. 22 Aug 2025Insiders record

    Hebbar Sudarshan (Chief Medical Officer) bought 9,563 shares of CALC ($26,968) (dated 21 Aug 2025)

  17. 20 Aug 2025Insiders record

    Roberts Eric W (CHIEF BUSINESS OFFICER) bought 5,076 shares of CALC ($14,720) (dated 19 Aug 2025)

  18. 19 Aug 2025Insiders record

    Hebbar Sudarshan (Chief Medical Officer) bought 5,976 shares of CALC ($16,356) (dated 18 Aug 2025)

  19. 30 Jul 2025Insiders record

    Stauderman Kenneth A. (Chief Scientific Officer) bought 1,000 shares of CALC ($3,960) (dated 29 Jul 2025)

  20. 24 Jul 2025Insiders record

    Roberts Eric W (CHIEF BUSINESS OFFICER) bought 1,500 shares of CALC ($5,670) (dated 23 Jul 2025)

  21. 23 Jul 2025Insiders record

    Roberts Eric W (CHIEF BUSINESS OFFICER) bought 1,500 shares of CALC ($5,055) (dated 22 Jul 2025)

  22. 22 Jul 2025Insiders record

    Leheny A. Rachel (CHIEF EXECUTIVE OFFICER) bought 1,000 shares of CALC ($3,400) (dated 21 Jul 2025)

  23. 19 Jul 2025Insiders record

    WILSON ROBERT N (director) bought 4,500 shares of CALC ($12,915) (dated 18 Jul 2025)

  24. 19 Jul 2025Insiders record

    Roberts Eric W (CHIEF BUSINESS OFFICER) bought 2,000 shares of CALC ($5,760) (dated 18 Jul 2025)

  25. 17 Jul 2025Insiders record

    Roberts Eric W (CHIEF BUSINESS OFFICER) bought 6,500 shares of CALC ($15,795) (dated 16 Jul 2025)

  26. 16 Jul 2025Insiders record

    Leheny A. Rachel (CHIEF EXECUTIVE OFFICER) bought 2,500 shares of CALC ($6,175) (dated 15 Jul 2025)

  27. 11 Jul 2025Insiders record

    Roberts Eric W (CHIEF BUSINESS OFFICER) bought 5,000 shares of CALC ($8,000) (dated 10 Jul 2025)

  28. 3 Jul 2025Insiders record

    Stauderman Kenneth A. (Chief Scientific Officer) bought 1,000 shares of CALC ($1,850) (dated 2 Jul 2025)

  29. 28 Jun 2025Insiders record

    Roberts Eric W (CHIEF BUSINESS OFFICER) bought 4,500 shares of CALC ($6,480) (dated 27 Jun 2025)

  30. 27 Jun 2025Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  31. 27 Jun 2025Filings record

    Director or officer change

  32. 27 Jun 2025Insiders record

    Bardin Stephen (Chief Financial Officer) bought 2,000 shares of CALC ($3,000) (dated 26 Jun 2025)

  33. 14 Jun 2025Insiders record

    Roberts Eric W (CHIEF BUSINESS OFFICER) bought 5,000 shares of CALC ($9,250) (dated 13 Jun 2025)

  34. 10 Jun 2025Insiders record

    Roberts Eric W (CHIEF BUSINESS OFFICER) bought 10,100 shares of CALC ($17,570) (dated 9 Jun 2025)

  35. 6 Jun 2025Filings record

    Changed its auditor

  36. 4 Jun 2025Insiders record

    Bardin Stephen (Chief Financial Officer) bought 1,000 shares of CALC ($1,690) (dated 3 Jun 2025)

  37. 14 Jan 2025Filings record

    Director or officer change

  38. 7 Dec 2024Insiders record

    MIDDLETON FRED A (director) bought 4,800 shares of CALC ($12,720) (dated 6 Dec 2024)

  39. 8 Nov 2024Filings record

    Director or officer change

  40. 7 Nov 2024Insiders record

    Roberts Eric W (CHIEF BUSINESS OFFICER) bought 3,000 shares of CALC ($8,040) [amended] (dated 6 Nov 2024)

Showing the newest 40 of 120 entries; narrow the window or the kind of data to see older ones.

Not listed: 87 routine records (quarterly and annual reports, results releases, other 8-K items, material agreements and individual insider sales), counted over all history.

Identifiers and sources

How records are matched to this company, and what each source holds for it

Cik
0001534133
Ticker
CALC
Domain
calcimedica.com
Hq location
CA|LA JOLLA|92037 (1 unverified)
Name
CalciMedica, Inc., GRAYBUG, Inc., GRAYBUG VISION, INC.
  • SEC Form 13F institutional holdings221 data points30 Sep 2020 to 30 Sep 2026
  • SEC EDGAR filings (8-K items, S-1, Form D, 10-K/10-Q)111 records13 May 2016 to 10 Nov 2026
  • SEC XBRL company facts (revenue, capex, R&D, backlog...)392 data points31 Dec 2018 to 5 Nov 2026
  • SEC Form 4 insider transactions85 records, 216 data points29 Sep 2020 to 29 Jun 2026
  • FINRA short interest (twice monthly)261 data points31 Mar 2023 to 30 Oct 2026
  • FINRA daily short sale volume (off-exchange)1734 data points21 Mar 2023 to 20 Nov 2026